Skip to content
value.today

Virdante Pharmaceuticals, Inc.

🇺🇸 Cambridge, Massachusetts, USAPharmaceuticalsFounded 2007
Total raised
$30 M
1 round on record
Latest round
$30 M
Jan 2008
First round on record
Jan 2008
Today
Private
No later event on record

Funding rounds

1 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Virdante Pharmaceuticals, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jan 2008$30 MNo. 1$10 to $50 million

Virdante Pharmaceuticals, Inc.: Raise no. 1, Jan 2008

Investors in this round

10 investors had bought by the notice of Oct 14, 2011: 10 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$30 M of $48 M offered; $18 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • John Ripple · Executive Officer, Director
  • Anders Patrick Hove · Director
  • Eric Patrick Aguiar · Director
  • Gail Patrick Wasserman · Director
  • L. Patrick Gage · Director
  • Michael Patrick Steinmetz · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by John Ripple, Chief Executive Officer. Newest notice filed Oct 14, 2011 (2 amendments). Read the notice at the SEC.

equitySEC

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Virdante Pharmaceuticals, Inc. chose not to state its revenue in its newest notice of a funding round (Oct 2011).

    SEC Form D · Oct 2011

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Oct 2011

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Virdante Pharmaceuticals, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Virdante Pharmaceuticals, Inc.
NameRoleNamed in
John RippleExecutive officerOct 2011
Anders Patrick HoveDirectorOct 2011
Eric Patrick AguiarDirectorOct 2011
Gail Patrick WassermanDirectorOct 2011
John RippleDirectorOct 2011
L. Patrick GageDirectorOct 2011
Michael Patrick SteinmetzDirectorOct 2011